Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

August 08, 2023 at 08:30 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023

IRVINE, CA / ACCESSWIRE / August 8, 2023 / Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15^th, 2023.

Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for the conference with their Needham representative.

About Oncocyte
Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/

VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com

SOURCE: Oncocyte
via PRISM Mediawire, LLC

View source version on accesswire.com:
https://www.accesswire.com/772720/Oncocyte-to-Participate-in-8th-Annual-Needham-Virtual-MedTech-Diagnostics-11-Conference

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article